Latest News - BioTime

Wednesday, March 07, 2018

BioTime Announces DSMB Approval to Proceed to Cohort 4 of the OpRegen Clinical Trial

BioTime announced that the independent Data Safety Monitoring Board (DSMB) has approved initiation of the fourth cohort for the ongoing OpRegen clinical trial. The DSMB is an independent group of medi…

Read the full story

Monday, August 14, 2017

BioTime Announces $2 Million Grant for Further Development of OpRegen for Dry AMD

BioTime has been awarded a new grant for 2017 of up to 7.2 million Israeli New Shekels (approximately $2 million) from the Israel Innovation Authority (IIA) to fund the continued development of OpRege…

Read the full story

Wednesday, July 19, 2017

Data From BioTime’s Phase 1/2a OpRegen Trial to be Presented at the 2017 AAO Annual Meeting

BioTime announced that an abstract related to the company’s retinal tissue implant has been accepted for a paper presentation at the American Academy of Ophthalmology (AAO) annual meeting being …

Read the full story

Monday, June 19, 2017

Biotime Expands & Advances Ophthalmology Portfolio

BioTime reported several developments for its ophthalmology portfolio, including: Signing a new and expanded licensing agreement with Hadassah Medical Organization of Jerusalem, Israel Present…

Read the full story

Thursday, May 11, 2017

BioTime Presents Retinal Restoration Data at ARVO

BioTime announced that a poster related to the company’s retinal restoration technology was presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in …

Read the full story

Wednesday, May 10, 2017

BioTime Announces New Positive Data from OpRegen Trial in Dry-AMD

BioTime announced new data from the phase 1/2a clinical trial of OpRegen in the advanced form of dry age-related macular degeneration (AMD). The interim data were presented on May 8, 2017 at the …

Read the full story